country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P11288A

Copy Link Print Information

ANT308 TFA

カスタマーレビュー

Based on 1 Customer Validation

ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.57%
分子式: C₁₅₆H₂₆₁N₄₇O₄₀S·xC₂HF₃O₂
分子量:3467.10 (free base)

保管条件:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ANT308 TFA 構造式

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

PACAP Receptor アイソフォーム固有の製品をすべて表示 :

体外実験

ANT308 (0.1-10 μM, 72 h) TFA reduces the viability of B16F10 and HT-144 cells dose-dependently^[2].
ANT308 (10 μM, 72 h) TFA decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells^[2].
ANT308 (10 μM, 8 h) TFA significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines^[2].
ANT308 (72 h) TFA reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

B16F10 and HT-144 cells
Concentration:

0.1, 1, 5 and 10 μM
Incubation Time:

72 h
Result:

Decreased the numbers of viable B16F10 and HT-144 cells by around 46% and 27%, respectively, compared to control cultures with 5 μM twice daily.

Cell Cycle Analysis^[2]

Cell Line:

B16LS9 and Mel 290 cells
Concentration:

10 μM
Incubation Time:

72 h
Result:

Decreased cells in the S phase.

Apoptosis Analysis^[2]

Cell Line:

B16LS9 and Mel 290 cells
Concentration:

10 μM
Incubation Time:

72 h
Result:

Increased percentages of apoptotic cells.

Cell Migration Assay ^[2]

Cell Line:

B16LS9, B16F10, Mel 290 cells, HT-144 cells
Concentration:

10 μM
Incubation Time:

8 h
Result:

Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines.

体内実験

ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) TFA reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)^[2]
Dosage:

100 μg/100 μL PBS
Administration:

Subcutaneous injection (s.c.), twice a day for 10 days
Result:

Significantly reduced the number of liver metastases.
Reduced MCAM, but had no significant effect on N-cadherin expression.
had no significant effect on subcutaneous tumor volume.

化学情報

性状 Solid
分子量 3467.10 (free base)
分子式 C₁₅₆H₂₆₁N₄₇O₄₀S·xC₂HF₃O₂
Color White to off-white
配列

Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
シーケンスの短縮

KPRRPYTSDYTRLRKQMAVKKYLNLILN
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Lester C, et al. Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide. Int J Mol Sci. 2024 Apr 16;25(8):4391.

[2]. Wang W, et al. Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Lett. 2025 Sep 28;628:217855. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外実験
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ANT308 TFA

Peptide Library

PACAP Receptor アイソフォーム固有の製品をすべて表示